Proton Pump Inhibitors Prescription Patterns: A Retrospective Analysis of Internal Medicine Wards Admissions of a Tertiary Hospital
Padrões de Prescrição de Inibidores da Bomba de Protões: Uma Análise Retrospetiva das Admissões em Enfermarias de Medicina Interna de um Hospital Terciário
DOI:
https://doi.org/10.24950/rspmi.2513Keywords:
Inappropriate Prescribing, Practice Patterns, Physicians, Proton Pump Inhibitors/economics, Proton Pump Inhibitors/therapeutic useAbstract
Introduction: Proton pump inhibitors (PPIs) have revolutionized the treatment of various medical conditions, including gastroesophageal reflux disease and peptic ulcer disease. Due to their affordability, widespread availability, and favourable safety profile, they are among the most commonly prescribed medications today. However, they are often prescribed without a valid medical reason, a practice that can be observed in up to 80% of cases.
Methods: A retrospective study was conducted with the
primary objective of assessing the proportion of patients on
PPIs and the presence or absence of a valid indication for their use. Additionally, we examined whether PPI usage had any impact on hospitalization duration and mortality. Finally, a brief cost analysis of these medications was performed. The study was carried out using a sample of patients admitted to a tertiary university hospital over nine months in internal medicine wards. Electronic records were consulted to collect pertinent information.
Results: A total of 164 patients, with an average age of
82.7 ± 10.6 years, were assessed. The mean length of hospitalization was 12.7 ± 10.0 days. Approximately 61% of patients on PPIs lacked a valid indication for their use, while
approximately one-fifth of patients not on PPIs had a valid
indication. In both patient groups, the most common indication for PPI usage was prophylaxis in high-risk patients taking nonsteroidal anti-inflammatory drugs (NSAIDs). PPIs did not demonstrate any influence on the length of hospitalization or mortality. On average, each patient on PPIs spent €25.8 per year, contributing to an unnecessary total public funds expenditure of €679.1 in the assessed sample.
Conclusion: Considering the advanced age of the individuals, many of them were taking NSAIDs or antiplatelet agents, which is likely the reason for PPI prescription even in the absence of a valid indication. Various efforts have been made to implement measures to reverse this prescribing trend, with some showing effectiveness, notably educational outreach visits.
Downloads
References
Connelly D: The development and safety of proton pump inhibitors. J Pharm. 2016; 296: doi: 10.1211/PJ.2016.20201343
Gamelas V, Salvado V, Dias L. Prescription Pattern of Proton Pump Inhibitors at Hospital Admission and Discharge. GE Port J Gastroenterol. 2019;26:114-20. doi:10.1159/000488506
Martín C, López J, Argüelles-Arias F. Safe use of proton-pump inhibitors. Rev Esp Enferm Dig. 2023, 115:475-9. doi:10.17235/reed.2023.9834/2023.
Luetzenberg FS, Jiang N. Practice patterns of reflux medication prescriptions in otolaryngology compared to other specialties. Laryngoscope. 2020;130:321-7. doi:10.1002/lary.27916
Xavier S, Magalhães J, Cotter J. Proton Pump Inhibitors: Are They a Real Threat to the Patient? GE Port J Gastroenterol. 2018;25:243-52.
doi:10.1159/000487154
Savarino V, Dulbecco P, Savarino E. Are proton pump inhibitors really so dangerous. Dig Liver Dis. 2016;48:851-9. doi:10.1016/j.dld.2016.05.018
Targownik LE, Fisher DA, Saini SD. AGA Clinical Practice Update on De-Prescribing of Proton Pump Inhibitors. Exp Rev Gastroenterol.
;162:1334-42. doi:10.1053/j.gastro.2021.12.247
Infarmed - Autoridade Nacional do Medicamento e Produtos de Saúde I.P. Guia dos Genéricos: Guia dos Preços de Referência [accessed June, 2023] Available at: https://app10.infarmed.pt/genericos/genericos_II/.
Lanas A, Ferrandez A. Inappropriate prevention of NSAID-induced gastrointestinal events among long-term users in the elderly. Drugs Aging. 2007;24:121-31. doi:10.2165/00002512-200724020-00004
Murthy SK, Kauldher S, Targownik LE. Physicians' approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users. Aliment Pharmacol Ther. 2006;23:1365-72. doi:10.1111/j.1365-2036.2006.02873.x
Song HJ, Jiang X, Henry L, Nguyen MH, Park H. Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis. Eur J Clin Pharmacol. 2020;76:851-66. doi:10.1007/s00228-020-02854-8
Tvingsholm SA, Dehlendorff C, Østerlind K, Friis S, Jäättelä M. Proton pump inhibitor use and cancer mortality. Int J Cancer. 2018;143:1315-26. doi: 10.1002/ijc.31529
Shiraev TP, Bullen A. proton pump inhibitors and cardiovascular events:a systematic review. Heart Lung Circ. 2018;27:443-50. doi: 10.1016/j.hlc.2017.10.020
Brown JP, Tazare JR, Williamson E, Mansfield KE, Evans SJ, Tomlinson LA, et al. Proton pump inhibitors and risk of all-cause and cause-specific mortality:A cohort study. Br J Clin Pharmacol. 2021;87:3150-61. doi: 10.1111/bcp.14728.
Lo CH, Ni P, Yan Y, Ma W, Joshi AD, Nguyen LH, et al. Association of Proton Pump Inhibitor Use With All-Cause and Cause-Specific Mortality. Gastroenterology. 2022;163:852-61.e2. doi: 10.1053/j.gastro.2022.06.067.
van Vliet EP, Otten HJ, Rudolphus A, Knoester PD, Hoogsteden HC, Kuipers EJ, et al. Inappropriate prescription of proton pump inhibitors on two pulmonary medicine wards. Eur J Gastroenterol Hepatol. 2008;20:608-12. doi:10.1097/MEG.0b013e3282f52f95
van Vliet EP, Steyerberg EW, Otten HJ, Rudolphus A, Knoester PD, Hoogsteden HC, et al. The effects of guideline implementation for proton pump inhibitor prescription on two pulmonary medicine wards. Aliment Pharmacol Ther. 2009;29:213-21. doi: 10.1111/j.1365-2036.2008.03875.x. Erratum in: Aliment Pharmacol Ther. 2009;29:350.
Farmer AP, Légaré F, Turcot L, Grimshaw J, Harvey E, McGowan JL, et al. Printed educational materials: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2008:CD004398. doi: 10.1002/14651858.CD004398.pub2. Update in: Cochrane Database Syst Rev. 2012;10:CD004398. doi: 10.1002/14651858.CD004398.pub3.
Flodgren G, Parmelli E, Doumit G, Gattellari M, O'Brien MA, Grimshaw J, et al. Local opinion leaders: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2011;CD000125. doi: 10.1002/14651858.CD000125.pub4. Update in: Cochrane Database Syst Rev. 2019;6:CD000125. doi: 10.1002/14651858.CD000125.pub5.
Jamtvedt G, Young JM, Kristoffersen DT, O'Brien MA, Oxman AD. Audit and feedback: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2012:CD000259. doi: 10.1002/14651858.CD000259.pub3
O'Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT, et al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007;2007:CD000409. doi: 10.1002/14651858.CD000409.pub2.
Valette S, Dory A, Gourieux B, Weber JC. Évaluation de l’implantation d’un processus de dé-prescription des inhibiteurs de la pompe à protons (IPP) à l’aide d’un algorithme au sein d’un service de médecine interne. Rev Med Interne. 2021;42:535-40. doi:10.1016/j.revmed.2020.11.014
By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67:674-94.
O'Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14:625-32. doi: 10.1007/s41999-023-00777-y. Erratum in: Eur Geriatr Med. 2023;14:633. doi: 10.1007/s41999-023-00812-y.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2024 Internal Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2023 Medicina Interna
Open Access
